GLP-1 drugs for kids: what the 'Ozempic era' trend gets wrong

What did @claraaaa_van actually say?

The claim is pretty simple: Baby Bottle Pops got smaller. @claraaaa_van noticed the candy looks "unoos and picked" compared to what she remembers, saying "they used to be fatters." She's connecting this product change to the so-called Ozempic era, implying GLP-1 drug popularity may be reshaping what food companies make or how much candy they put in a package.

To be fair, this is more of a casual cultural observation than a hard medical claim. She's not saying Ozempic caused shrinkflation, exactly. She's gesturing at a broader cultural moment. But the implication is there, and it's worth pulling apart, because some of it is actually grounded in something real, even if the packaging is sloppy.

Does the science back this up?

Sort of, but not in the way she's framing it. There is real evidence that GLP-1 receptor agonists reduce appetite and change food preference patterns. What's less established is whether that's directly reshaping candy manufacturing decisions.

The GLP-1 drug market has exploded. Semaglutide prescriptions in the U.S. grew dramatically between 2021 and 2023, with over 9 million Americans on a GLP-1 medication by late 2023, according to pharmacy benefit data reported by Reuters. Food industry analysts at Euromonitor and Morgan Stanley have published reports suggesting CPG (consumer packaged goods) companies are watching GLP-1 adoption closely, anticipating lower overall snack consumption. Bernstein Research analysts noted in 2023 that GLP-1 users reported reduced cravings for sugary, high-fat foods specifically. So the broader cultural-commercial anxiety is documented. Whether Baby Bottle Pop specifically changed its product dimensions because of this trend? That's unverifiable.

Shrinkflation, separately, is well documented and predates GLP-1 drugs. Edgar Dworsky, a consumer advocate who tracks product size changes, has documented hundreds of examples since 2008. Blaming Ozempic for a candy getting smaller, without evidence, conflates two real but separate phenomena.

What did they get wrong (or right)?

She got the cultural vibe right and the causal logic wrong. The "Ozempic era" framing as a shorthand for appetite suppression reshaping consumer culture is something serious food industry analysts are genuinely discussing. Credit where it's due.

But there are problems. First, shrinkflation has many causes: commodity cost increases, supply chain pressures, and inflation. The candy shrinking does not require a GLP-1 explanation. Second, the transcript is hard to parse. "Unoos and picked" likely means "unloaded and packed" or possibly just "smaller," but the audio is unclear enough that we can't be fully certain of her exact meaning, which matters when fact-checking a specific claim. Third, there is no published data showing Baby Bottle Pop changed its product size during the GLP-1 adoption surge. This would need to be verified directly with Bazooka Candy Brands, which manufactures the product.

So: culturally observant, causally thin, and missing the much more boring explanation that candy companies have been quietly downsizing products for cost reasons for over a decade.

What should you actually know?

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) do meaningfully reduce appetite and alter food preferences. A 2022 study by Friedrichsen et al. in Diabetes, Obesity and Metabolism found semaglutide reduced appetite, energy intake, and food cravings in people with obesity. Separate neuroimaging research has suggested GLP-1 agonists may dampen reward responses to high-calorie foods specifically.

Whether that translates to food companies changing product sizes is a market question, not a clinical one, and the evidence there is speculative. Food companies respond to sales data slowly. The GLP-1 adoption curve is steep but still represents a minority of U.S. consumers. Industry analysts are watching, but no peer-reviewed study has demonstrated a direct causal link between GLP-1 adoption and CPG product reformulation or downsizing.

The takeaway: GLP-1 drugs are real, their appetite effects are real, and the food industry is paying attention. But "Ozempic made my candy smaller" is a fun cultural meme, not a documented mechanism.

Bottom line

This video is low-stakes, but the pattern it represents matters. Attributing everyday product changes to GLP-1 drugs without evidence muddies public understanding of what these medications actually do and how markets actually work. The drugs are not magic cultural forces reshaping every candy aisle. They are medications with specific mechanisms, meaningful benefits, real side effects, and a regulatory pathway that requires a licensed provider. If you're curious about whether a GLP-1 medication is appropriate for you, that conversation starts with a clinician, not a TikTok about Baby Bottle Pops.